$SII

Sprott (NYSE:SII) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Royal Bank of Canada has raised its price target for Sprott (NYSE:SII) from $218 to $230, reiterating an "outperform" rating and suggesting a substantial upside for the stock. This comes after Sprott exceeded quarterly earnings expectations, reporting an EPS of $1.13 and revenue of $80.75 million. Despite analyst optimism, the stock saw a 5.3% decline to $144.30, though it maintains a consensus "Moderate Buy" rating.

Original reporting
MarketBeat · MarketBeat
Published May 7, 2026, 6:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 7, 2026, 7:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Sprott (NYSE:SII) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says — source image
Decision brief

The 30-second read

$SIIBullishMed
01

Why it matters

The upgrade suggests confidence in Sprott's growth prospects, potentially leading to increased investor interest.

02

Market read

The news is relevant primarily to investors and traders interested in the financial and resource sectors, with moderate influence on broader markets.

03

What to watch

Market-wide volatility or sector-specific risks could offset the positive outlook; earnings beat alone may not sustain upward momentum.

Relevance 6/10Timing: short to medium term (next 1-3 months)

Background

Sprott reported quarterly earnings exceeding expectations, prompting an analyst upgrade.

Company-level read

Ticker impact

$SIIBullishHigh confidence
Context

Primary focus of the news, significant impact expected.

Expected impact

Moderate upward movement in the short to medium term, with potential for continued growth as investor confidence improves.

Evidence & confidence

The analyst upgrade and earnings beat suggest underlying strength. The recent price decline may present a buying opportunity for long-term investors, while short-term traders should monitor support levels around current prices.

Market effects

Positive sentiment for the financial services and investment management sectors.

Limited; primarily affecting US-based investment firms.

Moderate; reflects broader investor confidence in financial equities but not a global macroeconomic shift.

Counterpoint

The recent price decline indicates possible profit-taking or short-term correction; the analyst upgrade may already be priced in.

Key entities

  • Royal Bank of Canada

    Major Canadian bank and financial services provider, issuing the analyst upgrade.

  • Sprott Inc.

    Investment management firm focused on precious metals and natural resources.

Related articles

$SIIMed

Sprott (SII) Q2 2026 Earnings Call Transcript

Sprott Asset Management, in its Q2 2026 earnings call, reported AUM of $55.6B at June 30, 2026, down from $65.1B on March 31. Average AUM rose to $63.9B. Net income was $34.3M and adjusted EBITDA $50.8M. Net redemptions were $0.4B, mainly from precious metals physical trusts. Sprott declared a $0.40 dividend per share.

$AMZNMed

Amazon’s $8B Nvidia Chip Leaseback Deal [2026]

Amazon is reportedly in talks to lease back $8B worth of Nvidia Grace Blackwell chips from a financing vehicle, moving them off its balance sheet. The deal, if finalized, would involve an SPV issuing debt to investors and leasing the chips back to Amazon for AWS data centers. Both companies have not confirmed the deal, and details are still under discussion. The structure is part of a broader trend of tech firms using off-balance-sheet financing for AI infrastructure.

$BACMed

Bank of America (BAC) Personal Retirement Strategy Tops $100 Billion In Assets

Bank of America (BAC) reports its Personal Retirement Strategy program has surpassed $100 billion in assets under management, driven by digital tools combining managed portfolios with personalized retirement planning. This milestone reflects strong client uptake and potential for fee-based revenue growth, aligning with the bank's broader digital engagement strategy.

$GMABMedAI 9/10

Genmab A/S: Genmab Announces Rinatabart Sesutecan (Rina-S) Phase 2 RAINFOL-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

Genmab A/S (Nasdaq: GMAB) announced Phase 2 trial results for rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer. The treatment showed a 45.9% objective response rate and a median duration of response of 12.1 months. The study included 109 patients and was presented at the IGCS Congress 2026. Rina-S is being evaluated in multiple Phase 3 trials for various gynecologic cancers.

$GMABMedAI 8/10

Genmab reports trial results for ovarian cancer drug candidate

Genmab (GMAB) reported Phase 1/2 trial results for rinatabart sesutecan in platinum-resistant ovarian cancer, showing a 45.9% response rate and median progression-free survival of 9.5 months. The trial involved 109 patients, with common side effects including fatigue, nausea, and anemia. The drug is being evaluated in four Phase 3 trials for various gynecologic cancers.